Bayer signs Chinese research deal
pharmafile | July 20, 2010 | News story | Research and Development | Bayer, China, gynaecology
Bayer is partnering with the People’s Liberation Army General Hospital in Beijing on research into women’s healthcare.
The People’s Liberation Army General Hospital (301 Hospital) will receive research funding from the pharma company and their scientists will be able to work at Bayer’s research facilities in Berlin.
Scientists from the recently established Bayer Schering Pharma global drug discovery-innovation centre in Beijing will participate in and co-ordinate the research projects.
Professor Andreas Busch, member of the board of management at Bayer and head of global drug discovery, said: “Working together with the experts from The People’s Liberation Army General Hospital will help us to bring new therapies faster to patients suffering from gynaecological diseases, like endometriosis and uterine fibroids. We are looking forward to a successful collaboration.”
The partners’ first project will focus on the establishment and analysis of disease models and disease understanding, but the project will expand into areas outside its initial gynaecological focus in the future.
Professor Guoquan Ren, head of 301 Hospital’s medical management division, said: “Endometriosis and uterine fibroids are severe diseases that significantly compromise the health and quality of life of women.
“Joining forces will allow us to take advantage of each other’s strengths which will for sure drive the research and innovation in these fields.”
301 Hospital employs more than 3,600 medical professionals across 12 medical specialty centres, 14 medical research centers and eight major laboratories, engaging in various medical disciplines such as otolaryngology, orthopedics, gynaecology, and gerontology, among others.
It is one of the biggest general hospitals in China and has gained a high reputation in gynaecology and obstetrics research and knowledge in treatment of patients suffering from related diseases.
Ben Adams
Related Content
Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
The Problem of Endometriosis in the UK
When did we decide it was an acceptable condition of womanhood in the UK to …
CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …
